Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
Status:
Terminated
Trial end date:
2018-08-06
Target enrollment:
Participant gender:
Summary
In this research study, the investigators are looking to see whether the combination of
arsenic trioxide with a tyrosine kinase inhibitor is safe, and what effects it has on chronic
myelogenous leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
National Institutes of Health (NIH) TEVA Teva Pharmaceuticals USA